Get notified of page updates
Public Policy Priorities
Review some of FORCE's current legislative and regulatory policy priorities that impact the hereditary cancer community.

Stay up to date on research and information

Sign Up for FORCE Newsletters

Policy Archive Successful Effort

Establishment of National HBOC Week and Previvor Day

Hereditary Cancer Awareness

On September 15th, 2010, in a unanimous show of support, the U.S. House of Representatives voted in favor of a Resolution sponsored by Rep. Wasserman Schultz (FL-20) establish National Hereditary Breast and Ovarian Cancer Week and National Previvor Day. National HBOC week is now recognized as an annual event, beginning the last Sunday in September and ending the first Saturday in October. National Previvor Day occurs on the Wednesday of that week. 

The timing—the transition between National Ovarian Cancer Awareness Month (September) and National Breast Cancer Awareness Month (October)—demonstrates the link between these two cancers. It is estimated that up to 25% of ovarian cancers are due to hereditary factors and approximately 10% of breast cancers are hereditary. FORCE is proud to have spearheaded this initiative to bring attention to hereditary breast and ovarian cancer (HBOC) syndromes and to recognize their impact on the families affected.

Read the text of the resolution, H Res #1522. 

 

Update: With the growth of the hereditary cancer community and expansion of FORCE's mission to serve a broader population, National Hereditary Cancer Week was instituted in 2020.

Take Action Now Become an Advocate 2024 Priorities Federal Policy State Policy Advocacy Archive

News Briefs

4/3/2024 - Submitted comments to Senator Cassidy and the HELP Committee in response to an RFI regarding oversight of clinical diagnostic tests, known as in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs).

3/15/2024 - Joined the Coalition to Increase Access to Cancer Care (CIACC) in comments to House leadership on efforts to strengthen the Employee Retirement Income Security Act (ERISA) and emphasize the need to pass the Cancer Drug Parity Act.

3/1/2024 - Provided feedback to CMS on the Medicare Advantage Advanced Notice and accompanying Part D Redesign Program provisions aimed at reducing and managing beneficiary out-of-pocket costs in the Medicare Part D program.

2/29/2024 - Wrote sponsors to endorse the BENEFIT Act, which would require the FDA to include in the benefit-risk assessment framework of a new drug application how patient experience data was considered in the review process.

More